Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration
- 1Department of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing 400016, China
- 2Department of Clinical Medicine, Chongqing Medical University, Chongqing 400016, China
Abstract
AIM: To evaluate and compare the efficacy and safety of two treat-and-extend (T&E) regimens (2- and 4-week intervals, Δ2w and Δ4w) of intravitreal conbercept injections in patients with neovascular age-related macular degeneration (nAMD). METHODS: This 24-month prospective randomized controlled trial at the First Affiliated Hospital of Chongqing Medical University included patients with nAMD. Eyes were randomly assigned (1:1) to receive intravitreal conbercept (0.5 mg) with T&E regimens using 2- or 4-week interval adjustments (Δ2w and Δ4w groups). Key outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), superficial vascular density (SVD), deep vascular density (DVD), and large-medium vascular density (LMVD) within the 3 mm macular foveal region. The primary endpoint was the mean change in BCVA from baseline to the 2-year follow-up (noninferiority cutoff: 4 letters). RESULTS: Ultimately, 61 participants (68 eyes) completed the 2-year study. Baseline characteristics were similar between the two groups. At week 96, the mean number of injections was 11.17±1.13 in the Δ2w group (36 eyes, with the mean age of 70.42±9.31y) and 9.84±1.02 in the Δ4w group (32 eyes, with the mean age of 71.25±9.99y; P<0.001). The mean changes in BCVA were 5.19±6.58 and 5.91±5.51 letters (P=0.528), and Δ4w being noninferior to Δ2w (difference: 0.71 letters; 95%CI: -3.67 to 2.24). The mean changes in CRT were -118.97±106.97 and -134.98±128.77 μm (P=0.406), and the mean changes in SFCT were -30.03±17.48 and -32.55±22.73 μm (P=0.538), respectively. No significant intergroup differences in vascular densities were observed. Type 1 macular neovascularization had a higher baseline BCVA and required more injections than those with other macular neovascularization subtypes. CONCLUSION: Intravitreal conbercept injections administered via 2- and 4-week intervals show similar efficacy and safety. The reduced injection frequency in the Δ4w regimen may help lower the overall treatment burden, and individualized therapy based on nAMD subtypes may further optimize clinical outcomes.
Related
- Comparative Study on the Efficacy of Intravitreal and Subconjunctival Simultaneous Injection of Conbercept Followed by Trabeculectomy Versus Intravitreal Injection of Conbercept Followed by Trabeculectomy Combined With 5-Fluorouracil (5-FU) in the Treatment of Neovascular Glaucoma (NVG).
- Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report
- Noninfectious intraocular inflammation with hypopyon after intravitreal aflibercept 8 mg injection for neovascular age-related macular degeneration: a case report
- Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study.
- Association Between the Social Deprivation Index and Neovascular Age-Related Macular Degeneration Outcomes
BibTeX
@article{ju2026efficacy,
title = {{Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration}},
author = {Huan Ju and Xuan-Heng Ding and Ling-Yi Jin and Xue-Feng Qin and Qing-Yue Luo and Xing Wang and Hui Peng},
journal = {International Journal of Ophthalmology},
year = {2026},
month = nov,
doi = {10.18240/ijo.2026.11.09},
url = {https://doi.org/10.18240/ijo.2026.11.09},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Efficacy and safety of intravitreal conbercept treat-and-extend regimens in neovascular age-related macular degeneration
AU - Huan Ju
AU - Xuan-Heng Ding
AU - Ling-Yi Jin
AU - Xue-Feng Qin
AU - Qing-Yue Luo
AU - Xing Wang
AU - Hui Peng
PY - 2026
DA - 2026/11/02
JO - International Journal of Ophthalmology
DO - 10.18240/ijo.2026.11.09
UR - https://doi.org/10.18240/ijo.2026.11.09
AB - AIM: To evaluate and compare the efficacy and safety of two treat-and-extend (T&E) regimens (2- and 4-week intervals, Δ2w and Δ4w) of intravitreal conbercept injections in patients with neovascular age-related macular degeneration (nAMD). METHODS: This 24-month prospective randomized controlled trial at the First Affiliated Hospital of Chongqing Medical University included patients with nAMD. Eyes were randomly assigned (1:1) to receive intravitreal conbercept (0.5 mg) with T&E regimens using 2- or 4-week interval adjustments (Δ2w and Δ4w groups). Key outcomes included best-corrected visual acuity (BCVA), central retinal thickness (CRT), subfoveal choroidal thickness (SFCT), superficial vascular density (SVD), deep vascular density (DVD), and large-medium vascular density (LMVD) within the 3 mm macular foveal region. The primary endpoint was the mean change in BCVA from baseline to the 2-year follow-up (noninferiority cutoff: 4 letters). RESULTS: Ultimately, 61 participants (68 eyes) completed the 2-year study. Baseline characteristics were similar between the two groups. At week 96, the mean number of injections was 11.17±1.13 in the Δ2w group (36 eyes, with the mean age of 70.42±9.31y) and 9.84±1.02 in the Δ4w group (32 eyes, with the mean age of 71.25±9.99y; P<0.001). The mean changes in BCVA were 5.19±6.58 and 5.91±5.51 letters (P=0.528), and Δ4w being noninferior to Δ2w (difference: 0.71 letters; 95%CI: -3.67 to 2.24). The mean changes in CRT were -118.97±106.97 and -134.98±128.77 μm (P=0.406), and the mean changes in SFCT were -30.03±17.48 and -32.55±22.73 μm (P=0.538), respectively. No significant intergroup differences in vascular densities were observed. Type 1 macular neovascularization had a higher baseline BCVA and required more injections than those with other macular neovascularization subtypes. CONCLUSION: Intravitreal conbercept injections administered via 2- and 4-week intervals show similar efficacy and safety. The reduced injection frequency in the Δ4w regimen may help lower the overall treatment burden, and individualized therapy based on nAMD subtypes may further optimize clinical outcomes.
SN - 2222-3959
SN - 2227-4898
ER -